Tedalinab
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB 2 receptor agonist. It has a very high selectivity of 4700x for CB 2 over the related CB 1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials. Many related compounds are known, most of which also show high CB 2 selectivity.
Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB 2 receptor agonist. It has a very high selectivity of 4700x for CB 2 over the related CB 1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials. Many related compounds are known, most of which also show high CB 2 selectivity.
See also
CBS-0550 Olorinab SER-601
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370055974 under CC BY-SA 4.0; modifications have been made.